Clinical significance of breast cancer susceptibility gene 1 expression in resected non-small cell lung cancer: A meta-analysis

Table 1 Basic characteristics of included studies

Ref.	Year	Country	Sample size	Positive, n (%)	TNM stage	Outcome	Source of HR	NOS score
Rosell et al[18]	2007	Spain	123	40 (32.5)	IB-IIIA	OS	R	6
Bartolucci et al[11]	2009	Italy	54	36 (66.7)	IB-IIB	OS/DFS	R	7
Ma et al[19]	2010	China	89	53 (59.6)	IIIA	OS/DFS	E	8
Leng et al[20]	2012	China	85	14 (16.5)	I- IV	OS/DFS	R	7
Gachechiladze et al[21]	2013	Israel	32	9 (28.1)	I- II	OS/DFS	E	7
Gachechiladze et al[21]	2013	Israel	58	15 (25.9)	III- IV	OS/DFS	E	7
Yu et al[22]	2013	China	80	36 (45)	I- IV	OS/DFS	E	7
Grossi et al[23]	2015	Italy	81	45 (55.6)	I A-IIIB	OS	R	6
Lafuente-Sanchis et al[24]	2015	Spain	64	30 (46.9)	I	DFS	R	7
Huang et al[12]	2016	China	84	11 (13.1)	II-III	DFS	R	8
Wang et al[25]	2017	China	70	NR	II-III	OS	R	6
Levallet et al[26]	2017	France	221	129 (58.4)	I- IV	OS/DFS	R	8

TNM: Tumor-node-metastasis; OS: Overall survival; DFS: Disease-free survival; HR: Hazard ratio; R: Reported; E: Estimated; NOS: Newcastle-Ottawa quality assessment scale.